Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism
✍ Scribed by Ortiz-Ferrón, Gustavo; Yerbes, Rosario; Eramo, Adriana; López-Pérez, Ana I; De Maria, Ruggero; López-Rivas, Abelardo
- Book ID
- 109846903
- Publisher
- Nature Publishing Group
- Year
- 2008
- Tongue
- English
- Weight
- 783 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0007-0610
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Among thyroid carcinomas, highly aggressive undifferentiated or anaplastic carcinomas still await effective therapeutic strategies. __R__‐roscovitine is a novel cyclin‐dependent kinase inhibitor in clinical trials as anti‐cancer agent. We have investigated the effects of __R__‐roscoviti
## Abstract Treatment of cancer cells with histone deacetylase inhibitors (HDACi) such as suberolylanilide hydroxamic acid (SAHA) activates genes that promote apoptosis. To enhance proapoptotic efficiency, SAHA has been used in combination with radiation, kinase inhibitors and cytotoxic drugs. Alth
Resistance to apoptosis plays an important role in tumors that are refractory to chemotherapy and ionizing radiation (IR). bax, which forms a heterddimer with bcl-2 and accelerates apoptosir, is not, or only weakly. expremed in most human breast cancer cells, and weak bax expression is considered to